New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam
| Autor: | Kevin D Betthauser, Bryan D. Lizza, Marin H. Kollef, Scott T. Micek, David J. Ritchie |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Tazobactam medicine.medical_specialty Carbapenem Microbial Sensitivity Tests Drug resistance medicine.disease_cause law.invention 03 medical and health sciences 0302 clinical medicine Antibiotic resistance law Drug Resistance Multiple Bacterial Internal medicine medicine Humans Pseudomonas Infections Pharmacology (medical) 030212 general & internal medicine Pharmacology 0303 health sciences 030306 microbiology Pseudomonas aeruginosa business.industry medicine.disease Antimicrobial Intensive care unit Anti-Bacterial Agents Cephalosporins Pneumonia Infectious Diseases Perspective business medicine.drug |
| Zdroj: | Antimicrob Agents Chemother |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.02318-20 |
| Popis: | Ceftolozane-tazobactam (C/T) is a new fifth-generation cephalosporin/beta-lactamase inhibitor combination approved by the Food and Drug Administration and the European Medicines Agency for treatment of complicated intraabdominal infections, complicated urinary tract infections, and hospital-acquired pneumonia in adult patients. This review will briefly describe the pharmacology of C/T and focus on the emerging clinical trial and real-world data supporting its current utilization. Additionally, our synthesis of these data over time has set our current usage of C/T at Barnes-Jewish Hospital (BJH). C/T is primarily employed as directed monotherapy at BJH when Pseudomonas aeruginosa isolates are identified with resistance to other beta-lactams. C/T can also be used empirically in specific clinical situations at BJH prior to microbiological detection of an antibiotic-resistant P. aeruginosa isolate. These situations include critically ill patients in the intensive care unit (ICU) setting, where there is a high likelihood of infection with multidrug-resistant (MDR) P. aeruginosa; patients failing therapy with a carbapenem; specific patient populations known to be at high risk for infection with MDR P. aeruginosa (e.g., lung transplant and cystic fibrosis patients); and patients know to have previous infection or colonization with MDR P. aeruginosa. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|